Accelerate Diagnostics Announces Final Terms of Rights Offering

       Accelerate Diagnostics Announces Final Terms of Rights Offering

Company previously announced plans to raise $20,000,000 to fund product
commercialization efforts

PR Newswire

TUCSON, Ariz., July 12, 2013

TUCSON, Ariz., July 12, 2013 /PRNewswire/ --Accelerate Diagnostics, Inc.
(NASDAQ: AXDX), an in vitro diagnostics company dedicated to providing
solutions for the global challenge of drug resistant organisms and hospital
acquired infections, announced today the final terms of its previously
announced $20,000,000 rights offering. The Company anticipates that the
rights offering will commence with the distribution of the final prospectus
and related materials to stockholders on or about July 18, 2013.

Under the terms of the rights offering, the Company is distributing, at no
charge to the holders of its common stock as of 5:00p.m., New York City time,
on July 8, 2013, which was established as the record date for the rights
offering, 0.064038 non-transferable subscription rights for each share of
common stock owned on the record date, as more fully described in the
prospectus relating to the rights offering. Each whole subscription right
will allow the holder thereof to subscribe to purchase one share of common
stock at a subscription price of $8.04 per share. In addition, any holder of
subscription rights exercising his, her or its basic subscription privilege in
full will be eligible to subscribe to purchase additional shares of common
stock at the same subscription price per share, subject to the conditions and
limitations described further in the prospectus. In the aggregate, the
Company intends to issue up to 2,487,562 shares of common stock in connection
with the rights offering.

The subscription rights may be exercised until 5:00p.m. New York City time,
on August 7, 2013, as more fully described in the prospectus. The rights
offering period may not be extended. Any fractional rights remaining after
aggregating all of the subscription rights issued to a stockholder will be
rounded down to the nearest whole number, and no stockholder will receive any
shares with respect to fractional rights that are rounded down.

The Company has received a standby commitment from Abeja Ventures, LLC, which
is owned by, among other individuals and entities, Lawrence Mehren, John
Patience, Jack Schuler and Matthew W. Strobeck, each of whom is a director of
the Company. The standby purchaser has agreed to purchase any and all shares
of common stock that are not subscribed for by stockholders in connection with
the rights offering. Upon completion of the rights offering, the Company will
receive gross proceeds of approximately $20,000,000 before expenses. The
purpose of this rights offering is to raise equity capital in a cost-effective
manner that gives all of the Company's existing stockholders the opportunity
to participate on a pro rata basis. The net proceeds of the offering will be
used for working capital and specifically to fund the Company's business plan
and product commercialization efforts.

A Registration Statement relating to these securities has been filed with the
SEC but has not yet become effective. The securities may not be sold nor may
offers to buy be accepted prior to the time the Registration Statement is
declared effective. A copy of the prospectus forming a part of the
Registration Statement may be obtained free of charge at the website
maintained by the SEC at or by contacting Steve Reichling at (520)
365-3100. For questions about the rights offering, including questions about
subscription procedures and requests for additional copies of the prospectus
once it has been filed, contact Broadridge Corporate Issuer Solutions, Inc. at
(855) 793-5068. Broadridge is acting as the Subscription and Information
Agent for the rights offering on behalf of the Company.

This press release shall not constitute an offer to sell or the solicitation
of an offer to buy nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such

About Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) is an in-vitro diagnostics company
focused on developing and commercializing innovative systems for the rapid
identification and antibiotic susceptibility testing of infectious pathogens.
The Company's revolutionary BACcel™ platform utilizes a proprietary
culture-free process with both genomic and phenotypic detection technologies
that significantly decreases time to result while achieving high sensitivity
and specificity. In addition to the BACcel system development pipeline, the
Company also owns and licenses its proprietary OptiChem™ surface coatings
technology, which has numerous applications for binding in bio-analytical
systems, such as microarrays. For more information, visit:

Forward-Looking Statements
This press release contains words such as "expects," "shall," "will,"
"believes" and other similar expressions that are intended to identify
forward-looking statements within the meaning of the Safe Harbor Provisions of
the Private Securities Litigation Reform Act of 1995. Such statements in this
announcement are made based on the Company's current beliefs, known events and
circumstances at the time of publication and, as such, are subject in the
future to unforeseen risks and uncertainties that could cause the Company's
results of operations, performance and achievements to differ materially from
current expectations expressed in, or implied by, these forward-looking
statements. For a full discussion of the Company's risks and uncertainties,
which could cause actual results to differ from those contained in the
forward-looking statements, see "Risk Factors" in Item 1A in the Company's
Transition Report on Form 10-KT, filed with the SEC on March 20, 2013. In
addition, the Company's forward-looking statements could be affected by
general industry and market conditions and growth rates. Except as required
by federal securities laws, the Company undertakes no obligation to update or
revise these forward-looking statements to reflect new events, uncertainties
or other contingencies.

SOURCE Accelerate Diagnostics, Inc.

Contact: Samantha McCue, +1-720-786-7000,
Press spacebar to pause and continue. Press esc to stop.